Study Summary
Evaluation the safety,tolerability, preliminary efficacy,and PK/PD of CD19-CD22 CAR-T cells for the treatment of acute B lymphocytic leukemia.
Want to learn more about this trial?
Request More InfoInterventions
CD19-CD22 CAR-T cellsBIOLOGICAL
A autologous doping CAR - T cells injection targets with CD19 and CD22，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion CD19-CD22 CAR-T cells .
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Hematology Department of ShanXi Cancer Hospital | Taiyuan | Shanxi | China |